Guardant Health Inc (NASDAQ:GH) has been assigned a consensus broker rating score of 1.40 (Strong Buy) from the five analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and four have assigned a strong buy rating to the company.
Brokers have set a 12-month consensus price target of $43.50 for the company and are anticipating that the company will post ($0.29) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Guardant Health an industry rank of 78 out of 255 based on the ratings given to its competitors.
A number of research firms have weighed in on GH. JPMorgan Chase & Co. began coverage on shares of Guardant Health in a report on Monday. They set an “overweight” rating and a $42.00 target price on the stock. Bank of America assumed coverage on shares of Guardant Health in a research note on Monday. They issued a “neutral” rating and a $37.00 price objective on the stock. Cowen assumed coverage on shares of Guardant Health in a research note on Monday. They issued an “outperform” rating on the stock. William Blair assumed coverage on shares of Guardant Health in a research note on Monday. They issued an “outperform” rating on the stock. Finally, Leerink Swann reaffirmed an “outperform” rating on shares of Guardant Health in a research note on Monday.
GH opened at $34.23 on Tuesday. Guardant Health has a fifty-two week low of $27.04 and a fifty-two week high of $44.25.
About Guardant Health
Guardant Health, Inc is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
Further Reading: What are CEFs?
Get a free copy of the Zacks research report on Guardant Health (GH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.